A Phase 3 interventional study of Ibuprofen 250 mg / Acetaminophen 500 mg and Ibuprofen 250 mg in Post-surgical Pain Following Extraction of Molar Teeth, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-08-30.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 3rd largest by enrollment, is one of 7 that started in 2015, is one of 22 in phase 3, and was the 48th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 568 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 10th largest by enrollment of the 71 interventional ones that give a count, is one of 2 that started in 2015, is one of 28 in phase 3, and was the 68th registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blind, placebo-controlled, parallel group, single-center study in approximately 560 subjects to determine the overall analgesic efficacy and safety of a fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation compared to ibuprofen 250 mg alone, acetaminophen 650 mg alone, and to placebo. Subjects will be healthy males and females aged 18-40 years, inclusive, who are experiencing post-operative pain following surgical extraction of 3 or more third molar teeth. Following extraction, subjects must experience, within 5 hours, post-surgical pain of at least moderate severity (on a 4-point categorical scale), confirmed by a Visual Analog Pain Severity Rating Scale (VAS PSR) of at least 50 mm on a 100 mm VAS PSR scale. Eligible subjects will be randomized to receive a single oral dose of study medication under double-blind conditions and then evaluated on site for 12 hours following administration of study medication. Subjects will provide self-ratings of pain severity and pain relief at various time points using categorical and numerical scales. Additionally, subjects will also evaluate the time to first perceptible relief and time to meaningful relief using a double stopwatch method. Finally, at 12 hours, subjects will complete a categorical Global Evaluation of the study medication. A review of any reported adverse events will also be completed.
This is a 12-hour, 4-arm, randomized, double blind, placebo-controlled, parallel group, single-center study in approximately 560 subjects to determine the overall analgesic efficacy and safety of a fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation (administered as two caplets of 125 mg/250 mg IBU/APAP) compared to ibuprofen 250 mg alone, acetaminophen 650 mg alone, and to placebo. Subjects will be healthy males and females aged 18-40 years, inclusive, otherwise healthy, who are experiencing post-operative pain following surgical extraction of 3 or more third molar teeth. Following extraction, subjects must experience, within 5 hours, post-surgical pain of at least moderate severity (on a 4-point categorical scale), confirmed by a Visual Analog Pain Severity Rating Scale (VAS PSR) of at least 50 mm on a 100 mm VAS PSR scale. Upon completion of the baseline scales, eligible subjects will be randomized to receive a single oral dose of study medication under double-blind conditions and then evaluated on site for 12 hours following administration of study medication. At 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post dose time points, subjects will provide: self-ratings of pain severity using the numerical and categorical PSRs; and self-ratings of pain relief at each time point using a categorical pain relief rating scale. At 12 hours, subjects will also complete a 6-point categorical Global Evaluation of the study medication. Additionally, subjects will also evaluate the time to first perceptible relief and time to meaningful relief using a double stopwatch method up to 12 hours post-dose or until the time of first rescue medication use, whichever is sooner. A review of any reported adverse events will also be completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
2 caplets of IBU 125 mg
Drug: Ibuprofen 250 mg
2 tablets of APAP 325 mg
Drug: Acetaminophen 650 mg
2 caplets of Placebo
Drug: Placebo
Drug page: Ibuprofen
2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
Also known as: IBU 250 / APAP 500
2 caplets of Ibuprofen 125 mg
Also known as: IBU 250
2 tablets of Acetaminophen 325 mg
Also known as: APAP 650
2 caplets of Placebo
Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8])
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (0-8): Time-weighted sum of pain intensity difference (PID) scores over 8 hours. SPID11 score range was -40 (worst score) to 80 (best score) for SPID 0-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
Time frame: 0 to 8 hours post-dose
Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 6 to 8 Hours Post-dose (SPID11 [6-8])
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (6-8): Time-weighted sum of PID scores over 6 to 8 hours. SPID11 score range was -15 (worst score) to 30 (best score) for SPID 6-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
Time frame: 6 to 8 hours post-dose
Time-weighted Sum of Pain Relief Rating (TOTPAR) From 0 to 8 Hours and 6 to 8 Hours Post-dose
TOTPAR: Time-weighted sum of Pain Relief Rating (PRR) scores over 0 to 8 and 6 to 8 hours. TOTPAR total score range: 0 (worst score) to 32 (best score) for TOTPAR 0-8 and 0 (worst score) to 12 (best score) for TOTPAR 6-8 hours. PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
Time frame: 0 to 8 hours, 6 to 8 hours post-dose
Time to Treatment Failure
Time to treatment failure was defined as the time interval from the study drug administration up to the first documentation of treatment failure. Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first.
Time frame: 0 to 12 hours post-dose
Cumulative Percentage of Participants With Treatment Failure at 6 and 8 Hours
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
Time frame: 6 hours, 8 hours post-dose
Time to Onset of Meaningful Pain Relief
Participants evaluated time to meaningful relief by stopping a second stopwatch labelled as "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0 to 12 hours post-dose
Time to Confirmed Onset of First Perceptible Relief
Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labeled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0 to 12 hours post-dose
Pain Relief Rating (PRR) Score
Participants answered a question: "how much relief do you have from your starting pain?" on a 5-point categorical pain relief rating scale. Scale ranges from 0= no relief to 4= complete relief.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Pain Intensity Difference on 11-Point Numerical Scale (PID11)
PID11: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on an 11-point numerical pain severity rating scale. PID11 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID11: -5 (worst score) to 10 (best score).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Pain Intensity Difference on 4-Point Categorical Scale (PID4)
PID4: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on a 4-point categorical pain severity rating scale. PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)
PRID4: sum of PID and PRR at each post-dose time points up to 12 hours. Score range for PRID: -1(worst score) to 7(best score). PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score). PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale (SPID11) From 0 to 2 Hours, 0 to 6 Hours and 0 to 12 Hours Post-dose
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11: Time-weighted sum of PID scores over 12 hours. SPID11 score range was -10 (worst score) to 20 (best score) for SPID 0-2, -30 (worst score) to 60 (best score) for SPID 0-6, -60 (worst score) to 120 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst) to 10 (best).
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 12 hours post-dose
Time-weighted Sum of Pain Intensity Difference Scores on 4-Point Categorical Scale (SPID4) From 0 to 2 Hours, 0 to 6 Hours, 0 to 8 Hours, 0 to 12 Hours and 6 to 8 Hours Post-dose
Pain intensity was assessed on a 4-point categorical pain severity rating scale. SPID4: Time-weighted sum of PID over post-dose time points. SPID4 score range was -2 (worst score) to 6 (best score) for SPID 0-2, -6 (worst score) to 18 (best score) for SPID 0-6, -8 (worst score) to 24 (best score) for SPID 0-8, -12 (worst score) to 36 (best score) for SPID 0-12 and -3 (worst score) to 9 (best score) for SPID 6-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12, 6 to 8 hours post-dose
Time-weighted Sum of Pain Relief Rating (TOTPAR) From 0 to 2 Hours, 0 to 6 Hours and 0 to 12 Hours Post Dose
TOTPAR: Time-weighted sum of PRR scores over 2, 6 and 12 hours. TOTPAR total score range: 0 (worst score) to 8 (best score) for TOTPAR 0-2, 0 (worst score) to 24 (best score) for TOTPAR 0-6, 0 (worst score) to 32 (best score) for TOTPAR 0-8, 0 (worst score) to 48 (best score) for TOTPAR 0-12. PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 12 hours post-dose
Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores on 4-Point Categorical Scale (SPRID4) Over 2, 6, 8, 12 and 6 to 8 Hours Post-dose
SPRID4: Time-weighted sum of PRR and PID based on 4 point categorical pain severity rating scale (PRID) with score range: -2(worst score) to 14 (best score) for SPRID 0-2, -6 (worst score) to 42 (best score) for SPRID 0-6, -8 (worst score) to 56 (best score) for SPRID 0-8, -12 (worst score) to 84 (best score) for SPRID 0-12 and -3 (worst score) to 21 (best score) for SPRID 6-8 hours. PRID: sum of PID and PRR at post-dose time point with score range: -1 (worst score) to 7 (best score). PID calculated by subtracting pain intensity score at post-dose time points (score range: 0 \[none\] to 3 \[severe\]) from baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline score of at least moderate were included). PID total possible score range: -1 (worst score) to 3(best score). PRR assessed on 5-point categorical scale with range: 0 =no relief to 4 =complete relief.
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12, 6 to 8 hours post-dose
Cumulative Percentage of Participants With Treatment Failure
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
Time frame: 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Cumulative Percentage of Participants With Confirmed First Perceptible Relief
Percentage of participants with confirmed first perceptible relief was reported. Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Cumulative Percentage of Participants With Meaningful Relief
Percentage of participants with meaningful relief was reported. Participants evaluated time to meaningful relief by stopping a second stopwatch labeled "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Participant's Global Evaluation of Study Medication
Participant global evaluation of study medication was performed at the 12-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0= Very poor, 1= Poor, 2= Fair, 3= Good, 4= Very Good and 5= Excellent.
Time frame: 0 to 12 hours post-dose
| Milestone | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Started | 56 | 172 | 175 | 165 |
| Completed | 55 | 172 | 173 | 160 |
| Not completed | 1 | 0 | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 5 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (0-8): Time-weighted sum of pain intensity difference (PID) scores over 8 hours. SPID11 score range was -40 (worst score) to 80 (best score) for SPID 0-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8]) | 4.1 ± 19.0 | 34.3 ± 19.6 | 28.9 ± 20.5 | 19.4 ± 20.0 |
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (6-8): Time-weighted sum of PID scores over 6 to 8 hours. SPID11 score range was -15 (worst score) to 30 (best score) for SPID 6-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 6 to 8 Hours Post-dose (SPID11 [6-8]) | 1.9 ± 8.8 | 11.3 ± 9.2 | 9.5 ± 8.9 | 5.6 ± 8.8 |
TOTPAR: Time-weighted sum of Pain Relief Rating (PRR) scores over 0 to 8 and 6 to 8 hours. TOTPAR total score range: 0 (worst score) to 32 (best score) for TOTPAR 0-8 and 0 (worst score) to 12 (best score) for TOTPAR 6-8 hours. PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0 to 8 hours | 5.3 ± 7.9 | 18.4 ± 8.5 | 15.4 ± 9.0 | 11.4 ± 9.1 |
| 6 to 8 hours | 2.3 ± 3.8 | 6.2 ± 4.1 | 5.1 ± 4.0 | 3.5 ± 4.0 |
Time to treatment failure was defined as the time interval from the study drug administration up to the first documentation of treatment failure. Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first.
| minutes | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Time to Treatment Failure | 107.0 ± 8.8 | 629.0 ± 9.2 | 608.5 ± 8.9 | 449.0 ± 8.8 |
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
| percentage of participants | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 6 hour | 67.9 ± 7.9 | 10.5 ± 8.5 | 21.7 ± 9.0 | 38.8 ± 9.1 |
| 8 hour | 69.6 ± 3.8 | 24.4 ± 4.1 | 33.1 ± 4.0 | 51.5 ± 4.0 |
Participants evaluated time to meaningful relief by stopping a second stopwatch labelled as "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| minutes | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Time to Onset of Meaningful Pain Relief | NA ± 8.8 | 47.9 ± 9.2 | 65.9 ± 8.9 | 56.6 ± 8.8 |
Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labeled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| minutes | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Time to Confirmed Onset of First Perceptible Relief | NA ± 8.8 | 21.3 ± 9.2 | 24.6 ± 8.9 | 24.2 ± 8.8 |
Participants answered a question: "how much relief do you have from your starting pain?" on a 5-point categorical pain relief rating scale. Scale ranges from 0= no relief to 4= complete relief.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 0.18 ± 0.39 | 0.51 ± 0.65 | 0.36 ± 0.61 | 0.50 ± 0.70 |
| 0.5 hour | 0.30 ± 0.46 | 1.29 ± 1.02 | 1.11 ± 0.97 | 1.20 ± 1.00 |
| 1 hour | 0.44 ± 0.63 | 2.19 ± 1.22 | 1.85 ± 1.18 | 1.86 ± 1.14 |
| 1.5 hour | 0.48 ± 0.74 | 2.47 ± 1.17 | 2.08 ± 1.25 | 1.90 ± 1.19 |
| 2 hour | 0.55 ± 0.96 | 2.65 ± 1.21 | 2.28 ± 1.33 | 1.86 ± 1.25 |
| 3 hour | 0.70 ± 1.09 | 2.75 ± 1.17 | 2.35 ± 1.36 | 1.66 ± 1.36 |
| 4 hour | 0.71 ± 1.16 | 2.71 ± 1.23 | 2.27 ± 1.39 | 1.55 ± 1.39 |
| 5 hour | 0.73 ± 1.21 | 2.64 ± 1.27 | 2.18 ± 1.37 | 1.50 ± 1.43 |
| 6 hour | 0.80 ± 1.31 | 2.36 ± 1.37 | 2.01 ± 1.42 | 1.29 ± 1.43 |
| 7 hour | 0.77 ± 1.31 | 2.04 ± 1.45 | 1.68 ± 1.43 | 1.14 ± 1.39 |
| 8 hour | 0.73 ± 1.24 | 1.75 ± 1.47 | 1.40 ± 1.41 | 1.03 ± 1.37 |
| 9 hour | 0.73 ± 1.23 | 1.41 ± 1.49 | 1.31 ± 1.45 | 0.95 ± 1.31 |
| 10 hour | 0.75 ± 1.24 | 1.20 ± 1.47 | 1.19 ± 1.43 | 0.95 ± 1.37 |
| 11 hour | 0.78 ± 1.29 | 1.06 ± 1.43 | 1.03 ± 1.40 | 0.88 ± 1.34 |
| 12 hour | 0.75 ± 1.25 | 0.97 ± 1.35 | 0.97 ± 1.40 | 0.85 ± 1.35 |
PID11: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on an 11-point numerical pain severity rating scale. PID11 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID11: -5 (worst score) to 10 (best score).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 0.0 ± 0.9 | 0.6 ± 1.2 | 0.5 ± 1.2 | 0.7 ± 1.3 |
| 0.5 hour | 0.2 ± 1.2 | 2.2 ± 2.2 | 1.8 ± 2.0 | 2.0 ± 2.0 |
| 1 hour | 0.2 ± 1.6 | 4.1 ± 2.6 | 3.3 ± 2.6 | 3.3 ± 2.4 |
| 1.5 hour | 0.1 ± 1.8 | 4.8 ± 2.7 | 3.9 ± 2.8 | 3.4 ± 2.6 |
| 2 hour | 0.2 ± 2.1 | 5.1 ± 2.7 | 4.3 ± 3.0 | 3.3 ± 2.7 |
| 3 hour | 0.6 ± 2.6 | 5.3 ± 2.7 | 4.5 ± 3.1 | 2.9 ± 2.9 |
| 4 hour | 0.6 ± 2.7 | 5.2 ± 2.8 | 4.3 ± 3.0 | 2.7 ± 3.1 |
| 5 hour | 0.7 ± 2.9 | 5.0 ± 2.9 | 4.2 ± 3.1 | 2.6 ± 3.1 |
| 6 hour | 0.7 ± 3.0 | 4.4 ± 3.0 | 3.8 ± 3.1 | 2.2 ± 3.1 |
| 7 hour | 0.6 ± 3.0 | 3.8 ± 3.3 | 3.1 ± 3.1 | 1.8 ± 3.0 |
| 8 hour | 0.6 ± 2.9 | 3.1 ± 3.3 | 2.6 ± 3.0 | 1.6 ± 3.0 |
| 9 hour | 0.6 ± 2.8 | 2.4 ± 3.2 | 2.3 ± 3.0 | 1.4 ± 2.9 |
| 10 hour | 0.7 ± 2.9 | 2.0 ± 3.1 | 1.9 ± 2.9 | 1.4 ± 3.0 |
| 11 hour | 0.7 ± 2.9 | 1.7 ± 3.0 | 1.6 ± 2.9 | 1.3 ± 2.9 |
| 12 hour | 0.7 ± 2.9 | 1.5 ± 2.9 | 1.6 ± 2.9 | 1.2 ± 2.8 |
PID4: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on a 4-point categorical pain severity rating scale. PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 0.00 ± 0.27 | 0.15 ± 0.47 | 0.12 ± 0.47 | 0.20 ± 0.51 |
| 0.5 hour | 0.05 ± 0.40 | 0.60 ± 0.74 | 0.46 ± 0.72 | 0.61 ± 0.73 |
| 1 hour | 0.04 ± 0.54 | 1.18 ± 0.90 | 0.89 ± 0.95 | 0.98 ± 0.86 |
| 1.5 hour | 0.00 ± 0.57 | 1.36 ± 0.89 | 1.09 ± 1.01 | 0.98 ± 0.86 |
| 2 hour | 0.05 ± 0.75 | 1.47 ± 0.96 | 1.22 ± 1.09 | 0.92 ± 0.90 |
| 3 hour | 0.16 ± 0.83 | 1.55 ± 0.93 | 1.25 ± 1.09 | 0.81 ± 0.93 |
| 4 hour | 0.16 ± 0.87 | 1.15 ± 0.96 | 1.21 ± 1.08 | 0.74 ± 0.94 |
| 5 hour | 0.14 ± 0.88 | 1.44 ± 1.00 | 1.13 ± 1.05 | 0.75 ± 0.95 |
| 6 hour | 0.16 ± 0.93 | 1.27 ± 1.04 | 1.02 ± 1.04 | 0.63 ± 0.97 |
| 7 hour | 0.13 ± 0.88 | 1.04 ± 1.09 | 0.83 ± 1.02 | 0.50 ± 0.97 |
| 8 hour | 0.11 ± 0.82 | 0.88 ± 1.07 | 0.67 ± 0.97 | 0.45 ± 0.92 |
| 9 hour | 0.11 ± 0.82 | 0.69 ± 1.06 | 0.60 ± 0.95 | 0.36 ± 0.88 |
| 10 hour | 0.13 ± 0.85 | 0.52 ± 1.02 | 0.50 ± 0.95 | 0.37 ± 0.91 |
| 11 hour | 0.13 ± 0.85 | 0.45 ± 0.97 | 0.40 ± 0.93 | 0.32 ± 0.87 |
| 12 hour | 0.13 ± 0.85 | 0.38 ± 0.92 | 0.39 ± 0.96 | 0.27 ± 0.85 |
PRID4: sum of PID and PRR at each post-dose time points up to 12 hours. Score range for PRID: -1(worst score) to 7(best score). PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score). PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 0.2 ± 0.5 | 0.7 ± 1.0 | 0.5 ± 1.0 | 0.7 ± 1.1 |
| 0.5 hour | 0.4 ± 0.7 | 1.9 ± 1.7 | 1.6 ± 1.6 | 1.8 ± 1.6 |
| 1 hour | 0.5 ± 1.0 | 3.4 ± 2.0 | 2.7 ± 2.0 | 2.8 ± 1.9 |
| 1.5 hour | 0.5 ± 1.2 | 3.8 ± 2.0 | 3.2 ± 2.2 | 2.9 ± 1.9 |
| 2 hour | 0.6 ± 1.6 | 4.1 ± 2.1 | 3.5 ± 2.4 | 2.8 ± 2.1 |
| 3 hour | 0.9 ± 1.8 | 4.3 ± 2.0 | 3.6 ± 2.4 | 2.5 ± 2.2 |
| 4 hour | 0.9 ± 1.9 | 4.2 ± 2.1 | 3.5 ± 2.4 | 2.3 ± 2.3 |
| 5 hour | 0.9 ± 2.0 | 4.1 ± 2.2 | 3.3 ± 2.4 | 2.2 ± 2.3 |
| 6 hour | 1.0 ± 2.2 | 3.6 ± 2.3 | 3.0 ± 2.4 | 1.9 ± 2.3 |
| 7 hour | 0.9 ± 2.1 | 3.1 ± 2.5 | 2.5 ± 2.4 | 1.6 ± 2.3 |
| 8 hour | 0.8 ± 2.0 | 2.6 ± 2.5 | 2.1 ± 2.3 | 1.5 ± 2.2 |
| 9 hour | 0.8 ± 2.0 | 2.1 ± 2.5 | 1.9 ± 2.3 | 1.3 ± 2.1 |
| 10 hour | 0.9 ± 2.0 | 1.7 ± 2.4 | 1.7 ± 2.3 | 1.3 ± 2.2 |
| 11 hour | 0.9 ± 2.1 | 1.5 ± 2.3 | 1.4 ± 2.3 | 1.2 ± 2.1 |
| 12 hour | 0.9 ± 2.0 | 1.3 ± 2.2 | 1.4 ± 2.3 | 1.1 ± 2.1 |
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11: Time-weighted sum of PID scores over 12 hours. SPID11 score range was -10 (worst score) to 20 (best score) for SPID 0-2, -30 (worst score) to 60 (best score) for SPID 0-6, -60 (worst score) to 120 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst) to 10 (best).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0 to 2 hours | 0.3 ± 2.9 | 7.7 ± 4.4 | 6.3 ± 4.6 | 5.7 ± 4.1 |
| 0 to 6 hours | 2.9 ± 13.5 | 27.5 ± 14.4 | 23.1 ± 15.6 | 16.0 ± 14.9 |
| 0 to 12 hours | 6.8 ± 30.0 | 41.8 ± 28.7 | 36.3 ± 29.3 | 24.7 ± 29.5 |
Pain intensity was assessed on a 4-point categorical pain severity rating scale. SPID4: Time-weighted sum of PID over post-dose time points. SPID4 score range was -2 (worst score) to 6 (best score) for SPID 0-2, -6 (worst score) to 18 (best score) for SPID 0-6, -8 (worst score) to 24 (best score) for SPID 0-8, -12 (worst score) to 36 (best score) for SPID 0-12 and -3 (worst score) to 9 (best score) for SPID 6-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0 to 2 hours | 0.1 ± 0.9 | 2.2 ± 1.5 | 1.7 ± 1.7 | 1.6 ± 1.4 |
| 0 to 6 hours | 0.7 ± 4.2 | 8.0 ± 4.9 | 6.4 ± 5.5 | 4.6 ± 4.7 |
| 0 to 8 hours | 0.9 ± 5.8 | 9.9 ± 6.6 | 7.9 ± 7.1 | 5.5 ± 6.2 |
| 0 to 12 hours | 1.4 ± 9.0 | 11.9 ± 9.6 | 9.8 ± 9.9 | 6.8 ± 9.0 |
| 6 to 8 hours | 0.4 ± 2.6 | 3.2 ± 3.0 | 2.5 ± 2.9 | 1.6 ± 2.7 |
TOTPAR: Time-weighted sum of PRR scores over 2, 6 and 12 hours. TOTPAR total score range: 0 (worst score) to 8 (best score) for TOTPAR 0-2, 0 (worst score) to 24 (best score) for TOTPAR 0-6, 0 (worst score) to 32 (best score) for TOTPAR 0-8, 0 (worst score) to 48 (best score) for TOTPAR 0-12. PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0 to 2 hours | 0.9 ± 1.2 | 4.1 ± 2.0 | 3.5 ± 2.0 | 3.2 ± 1.9 |
| 0 to 6 hours | 3.8 ± 5.6 | 14.6 ± 6.3 | 12.3 ± 6.8 | 9.2 ± 6.7 |
| 0 to 12 hours | 8.3 ± 12.7 | 23.0 ± 12.7 | 19.9 ± 13.2 | 15.0 ± 13.4 |
SPRID4: Time-weighted sum of PRR and PID based on 4 point categorical pain severity rating scale (PRID) with score range: -2(worst score) to 14 (best score) for SPRID 0-2, -6 (worst score) to 42 (best score) for SPRID 0-6, -8 (worst score) to 56 (best score) for SPRID 0-8, -12 (worst score) to 84 (best score) for SPRID 0-12 and -3 (worst score) to 21 (best score) for SPRID 6-8 hours. PRID: sum of PID and PRR at post-dose time point with score range: -1 (worst score) to 7 (best score). PID calculated by subtracting pain intensity score at post-dose time points (score range: 0 \[none\] to 3 \[severe\]) from baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline score of at least moderate were included). PID total possible score range: -1 (worst score) to 3(best score). PRR assessed on 5-point categorical scale with range: 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0 to 2 hours | 0.9 ± 2.0 | 6.3 ± 3.3 | 5.2 ± 3.5 | 4.9 ± 3.1 |
| 0 to 6 hours | 4.5 ± 9.3 | 22.5 ± 10.7 | 18.6 ± 11.9 | 13.8 ± 11.0 |
| 0 to 8 hours | 6.2 ± 13.0 | 28.2 ± 14.5 | 23.2 ± 15.7 | 16.9 ± 14.8 |
| 0 to 12 hours | 9.7 ± 20.5 | 34.9 ± 21.5 | 29.6 ± 22.5 | 21.9 ± 21.6 |
| 6 to 8 hours | 2.7 ± 6.1 | 9.3 ± 6.9 | 7.6 ± 6.7 | 5.0 ± 6.6 |
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
| percentage of participants | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 1.5 hour | 39.3 | 2.9 | 6.9 | 6.7 |
| 2 hour | 51.8 | 4.1 | 10.3 | 10.3 |
| 3 hour | 62.5 | 7.0 | 13.1 | 18.8 |
| 4 hour | 64.3 | 7.6 | 16.6 | 27.9 |
| 5 hour | 66.1 | 8.1 | 18.3 | 35.2 |
| 6 hour | 67.9 | 10.5 | 21.7 | 38.8 |
| 7 hour | 69.6 | 16.9 | 25.7 | 44.2 |
| 8 hour | 69.6 | 24.4 | 33.1 | 51.5 |
| 9 hour | 69.6 | 35.5 | 42.3 | 56.4 |
| 10 hour | 69.6 | 46.5 | 48.6 | 60.0 |
| 11 hour | 69.6 | 51.7 | 55.4 | 62.4 |
| 12 hour | 71.4 | 55.8 | 60.0 | 63.6 |
Percentage of participants with confirmed first perceptible relief was reported. Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| percentage of participants | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 8.9 | 29.7 | 25.1 | 26.1 |
| 0.5 hour | 16.1 | 66.9 | 61.7 | 57.0 |
| 1 hour | 21.4 | 81.4 | 77.1 | 71.5 |
| 1.5 hour | 25.0 | 84.9 | 79.4 | 71.5 |
| 2 hour | 25.0 | 85.5 | 79.4 | 71.5 |
| 3 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 4 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 5 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 6 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 7 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 8 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 9 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 10 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 11 hour | 28.6 | 86.6 | 79.4 | 71.5 |
| 12 hour | 28.6 | 86.6 | 79.4 | 71.5 |
Percentage of participants with meaningful relief was reported. Participants evaluated time to meaningful relief by stopping a second stopwatch labeled "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| percentage of participants | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| 0.25 hour | 0.0 | 1.2 | 0.0 | 1.8 |
| 0.5 hour | 0.0 | 21.5 | 13.7 | 21.8 |
| 1 hour | 3.6 | 59.3 | 46.3 | 52.1 |
| 1.5 hour | 8.9 | 68.6 | 60.0 | 58.2 |
| 2 hour | 16.1 | 82.0 | 75.4 | 67.3 |
| 3 hour | 21.4 | 82.0 | 75.4 | 67.3 |
| 4 hour | 23.2 | 83.1 | 77.1 | 67.9 |
| 5 hour | 26.8 | 84.3 | 78.3 | 69.1 |
| 6 hour | 26.8 | 85.5 | 78.9 | 69.7 |
| 7 hour | 26.8 | 85.5 | 78.9 | 69.7 |
| 8 hour | 26.8 | 85.5 | 78.9 | 70.3 |
| 9 hour | 26.8 | 85.5 | 78.9 | 71.5 |
| 10 hour | 28.6 | 85.5 | 79.4 | 71.5 |
| 11 hour | 28.6 | 85.5 | 79.4 | 71.5 |
| 12 hour | 28.6 | 85.5 | 79.4 | 71.5 |
Participant global evaluation of study medication was performed at the 12-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0= Very poor, 1= Poor, 2= Fair, 3= Good, 4= Very Good and 5= Excellent.
| units on a scale | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| Participant's Global Evaluation of Study Medication | 1.0 ± 1.4 | 3.4 ± 1.2 | 3.0 ± 1.4 | 2.6 ± 1.5 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/56 (0%) | 19/56 (33.9%) |
| Ibuprofen 250 mg + Acetaminophen 500 mg | — | 0/172 (0%) | 21/172 (12.2%) |
| Ibuprofen 250 mg | — | 0/175 (0%) | 37/175 (21.1%) |
| Acetaminophen 650 mg | — | 0/165 (0%) | 41/165 (24.8%) |
| Event | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 17/56 | 17/172 | 24/175 | 33/165 |
| VomitingGastrointestinal disorders | 11/56 | 7/172 | 15/175 | 20/165 |
| DizzinessNervous system disorders | 4/56 | 5/172 | 6/175 | 12/165 |
| FlushingVascular disorders | 2/56 | 0/172 | 2/175 | 1/165 |
| HeadacheNervous system disorders | 0/56 | 0/172 | 3/175 | 4/165 |
Full analysis set (FAS) included all randomized participants who were dosed with the study medication and provided a baseline assessment.
| Age, Continuous(years) | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|
| Mean | 19.6 ± 3.0 | 19.3 ± 1.8 | 19.7 ± 2.7 | 19.4 ± 2.1 | 19.5 ± 2.3 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 250 mg | Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|
| Female | 34 | 102 | 102 | 97 | 335 |
| Male | 22 | 70 | 73 | 68 | 233 |
Ran from Sep 2015 to primary completion in Jun 2016, 9 months.
Results were first posted in Aug 2017, 1 year 2 months after primary completion.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen